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Angiogenesis is essential for tumor growth,
1 and it has been 
shown that anti-angiogenic therapy has been proven to be 
effective in several cancers such as colorectal cancer
2,3 and 
hepatocellular carcinoma (HCC).
4 Currently available anti- 
angiogenic cancer chemotherapy targets the vascular endothelial 
growth factor (VEGF) pathway by VEGF monoclonal antibody 
(bevacizumab)
3 or multi-targeted receptor tyrosine kinase 
inhibitors (sorafenib).
4 Hypoxia-inducible factor 1 (HIF-1) is a 
heterodimer protein which is composed of oxygen-regulated 
HIF-1α subunit and constitutively expressed HIF-1β subunit.
5,6 
Under normoxic condition, the degradation of HIF-1α subunit is 
facilitated by ubiquitination following the hydroxylation of 
proline residue(s). However, under hypoxic condition, stability 
of HIF-1α increases due to suppressed proline hydroxylation, 
leading to increased transcription of genes associated with 
adaptive homeostatic response to hypoxia such as erythropoiesis, 
glucose metabolism and angiogenesis.
7 In addition to intratumoral 
hypoxia, loss of function of tumor-suppressor genes also 
contributes to over-expression of HIF-1α in various human 
cancers.
6 HIF-1 is a key regulatory factor for angiogenesis in 
response to hypoxia: it induces expression of angiogenic growth 
factors such as VEGF, stromal derived factor 1, angiopoietin 2, 
placental growth factor, platelet-derived growth factor B and 
stem cell factor.
8 Many human cancers over-express HIF-1α, and 
expression of HIF-1α is associated with poor prognosis.
6,9 In 
hepatitis B virus-associated HCC, high expression of HIF-1α is 
found in half of tumor specimens and correlated with venous 
invasion and lymph node invasion.
10 These findings suggest the 
possibility of HIF-1α as a novel therapeutic target in HCC.
In the current issue, Choi et al. suppressed HIF-1α by 
adenovirus-mediated small hairpin RNA and observed that 
proliferation of hepatoma cell lines was suppressed and the new 
vessel formation by vascular endothelial cells was inhibited.
11 
This suppressive effect against hepatoma cells is concordant with 
the report by WeiXing et al. which knocked down HIF-1α by 
antisense oligonucleotide.
12 In the current study, however, the 
mechanisms by which HIF-1α directly inhibits the proliferation 
of hepatoma cell lines were not examined. In hypoxic state, 
HIF-1 can either induce or inhibit apoptosis.
13 Moreover, a recent 
report shows that knock-down of HIF-1α causes reciprocal 
increase of HIF-2α and vice versa, leading to attenuated 
apoptosis in HepG2 cells.
14 Therefore, further studies are 
warranted to examine the effects of HIF-1α on the apoptosis and 
proliferation of HCC in hypoxic state.
Recent reports including this study by Choi et al. have 
demonstrated that knock-down of HIF-1α by small interfering 
RNA
15 or short hairpin RNA can disrupt angiogenesis by HUVEC 
cells. However, the therapeutic potential of anti-angiogenic 
effect by targeting HIF-1 needs to be further validated in animal 
HCC models. One recent study targeting HIF-1α showed 
suppressed tumor growth and microvessel density in a murine 
subcutaneous HCC model.
16 However, two reports assessing the 
effect of HIF-1α on the tumor growth in orthotopic hepatoma 
models showed conflicting results.
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the action of HIF-1 may be influenced by the types of tumor cells 
and/or the stromal components of the tumor.
9 Further animal 
studies are also warranted to examine the efficacy of combination 
therapy that includes HIF-1α targeting and conventional types of 
anti-cancer drugs.
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